Table 1.
Binding capacity, neutralizing activity, and gene family analysis of 13 monoclonal Abs isolated from Patient #5, Patient #2, and Patient #22.
| Patient | mAbs | Binding to RBD | Pseudovirus (μg/ml) | Live virus (μg/ml) | Heavy chain | Kappa chain (K) or Lambda chain (L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kd (nM) | Competing w/ ACE2 | IC50 | IC80 | IC50 | IC80 | IGHV | HCDR3 | HCDR3 length | SHM (%) | IGK(L)V | K(L)CDR3 | K(L)CDR3 length | SHM (%) | ||
| P#5 | P5A-1B9 | 3.41 | +++ | 0.0014 | 0.0053 | 0.0043 | 0.0441 | 4-59*01 | ASNGQYYDILTGQPPDYWYFDL | 22 | 0.70 | K4-1*01 | QQYYSTPLT | 9 | 0.00 |
| P#22 | P22A-1D1 | 5.79 | +++ | 0.0038 | 0.0625 | 0.0198 | 0.1321 | 3-53*01 | ARDRDYYGMDV | 11 | 0.00 | K1-9*01 | LHLNSYRT | 8 | 0.38 |
| P#5 | P5A-2G7 | 3.95 | +++ | 0.0044 | 0.0287 | 0.1814 | 0.8355 | 4-61*01 | ARERCYYGSGRAPRCVWFDP | 20 | 0.34 | L2-14*01 | SSYTSSSTLVV | 11 | 0.74 |
| P#5 | P5A-1D1 | 6.83 | +++ | 0.0096 | 0.0691 | 0.0189 | 0.0743 | 3-53*01 | ARDLYYYGMDV | 11 | 0.35 | K1-9*01 | QQLNSYPT | 8 | 0.76 |
| P#5 | P5A-1B8 | 4.28 | +++ | 0.0115 | 0.0501 | 0.0168 | 0.0857 | 3-53*01 | ARETLAFDY | 9 | 1.40 | K1-9*01 | QQLNSYPPA | 9 | 0.00 |
| P#5 | P5A-2G9 | 15.94 | +++ | 0.0158 | 0.1466 | 0.0113 | 0.1187 | 3–33*01,3–33*06 | ARWFHTGGYFDY | 12 | 0.00 | L5-37*01 | MIWPSNALYV | 10 | 0.35 |
| P#5 | P5A-1D2 | 14.02 | +++ | 0.0186 | 0.1025 | 0.0273 | 0.4325 | 3-53*01 | ARALQVGATSDYFDY | 15 | 1.40 | L1-40*01 | QSCDSSLSVVV | 11 | 1.11 |
| P#5 | P5A-3C8 | 1.30 | +++ | 0.0206 | 0.1031 | 0.0112 | 0.1499 | 3-53*01 | ARDLQEHGMDV | 11 | 1.05 | K1-9*01 | QHLNSYPPGYT | 11 | 1.14 |
| P#2 | P2C-1F11* | 3.64 | +++ | 0.0286 | 0.1195 | 0.0323 | 0.1779 | 3-66*01,3-66*04 | ARDLVVYGMDV | 11 | 1.75 | K3-20*01 | QQYGSSPT | 8 | 0.00 |
| P#2 | P2B-2F6* | 5.57 | +++ | 0.0500 | 0.6074 | 0.4074 | 2.4309 | 4-38-2*02 | ARAVVGIVVVPAAGRRAFDI | 20 | 0.69 | L2-8*01 | SSYAGSNNLV | 10 | 0.00 |
| P#2 | P2B-1A10 | 38.41 | +++ | 0.0974 | 0.7446 | 0.0639 | 0.3053 | 3-53*01 | AREGPKSITGTAFDI | 15 | 0.35 | K1-33*01,K1D-33*01 | QQYDNLPMYT | 10 | 0.38 |
| P#5 | P5A-3B4 | 1.16 | + | 0.0993 | 1.0657 | 0.0561 | 1.0080 | 5-51*01 | ARRDSTYGGNTDY | 13 | 0.35 | L1-44*01 | AAWDDSLNGVV | 11 | 0.00 |
| P#5 | P5A-3C12 | 8.47 | +++ | 0.0996 | 0.4679 | 0.2636 | 2.6783 | 2–5*02 | AHSLFLTVGYSSSWSPFDY | 19 | 0.00 | K4-1*01 | QQYYSTPHT | 9 | 0.00 |
The program IMGT/V-QUEST was applied to analyze gene germline, complementarity determining region (CDR) 3 length, and somatic hypermutation (SHM). The CDR3 length was calculated from amino acids sequences. The SHM frequency was calculated from the mutated nucleotides. Antibody binding to RBD was presented either by KD or by competing with ACE2 where “+++” indicates >80% competition and “+” 20–50%. IC50 represents the half-maximal whereas IC80 the 80% inhibitory concentrations in the pseudovirus and live SARS-CoV-2 neutralization assay.
*Published in the reference (Ju, et al. 19).